Venture capital fund · 3 deals
Every published round Oncology Ventures took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Lumonus | Series B | Mar 2026 | $3m | Participant | Startup Daily (6 Mar 2026), Startup Daily (6 Mar 2026), SmartCompany | |
| Lumonus | Series B | Mar 2026 | $28m | Participant | Forbes Australia, SmartCompany, Investible, Investible portfolio | |
| Lumonus | Series B | Nov 2025 | $25m | Participant | Startup Daily (6 Mar 2026), Startup Daily (6 Mar 2026), Startup Daily (9 Nov 2025), SmartCompany (7 Nov 2025), SmartCompany (7 Nov 2025) |
Companies Oncology Ventures has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Lumonus | AI-native digital oncology platform automating radiation oncology workflows | Nov 2025, Series B | 3 | 0 |
Fund closes reported for Oncology Ventures, as distinct from the investments it has made.
Companies Oncology Ventures has backed that another company then bought. An exit for the holding, not a deal Oncology Ventures did.
Stories naming Oncology Ventures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A weekly roundup detailing new funding rounds for six Australian startups: Lyka, PlasmaLeap, Firmable, Veyor, Lumonus and Future Minds Network, with investors and round details.
Investible announces it backed Lumonus' A$28 million round with three co-investors, the first deal from its new early-stage fund; Lumonus builds AI software that automates cancer clinic workflows.
Roundup of eight funding deals: Synchron's Series D, plus raises by Lumonus AI, Hullbot, Nbryo, Cytophenix, Giftbee, Understanding Zoe and Zeligate, spanning medtech, robotics, agtech and AI.
Also Startup Daily·Startup Daily·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily
Sydney health-tech firm Lumonus AI has secured a $25 million Series B led by Aviron Investment Management with returning backer Oncology Ventures, to grow its US presence and develop medical-data tools.